2899-LB: Improvement in Glycemic Outcomes over 6 Months with Stelo Use: Analysis of 12,000 People with Non-Insulin Treated Type 2 Diabetes

Introduction and Objective: The Stelo glucose biosensor is an over-the-counter CGM for use in adults not on insulin that provides glucose insights on diet and exercise. This study describes glycemic outcomes over 6 months from a cohort of Stelo users with self-reported T2D. Methods: This retrospective analysis included 12,008 Stelo users ≥18 years (mean age 57 years, 54% men), who reported T2D not on insulin (NIT) and had ≥90 days of Stelo use, and baseline time in range (TIR) 70-180 mg/dL ≤70%. Change in CGM metrics and hyperglycemic excursions (the number of events with glucose levels >180 mg/dL for ≥2 hours) from baseline to 3 and 6 months were analyzed. Results: Compared to baseline, significant improvement was observed at 3 months with continued improvement at 6 months (Table) for all CGM metrics not at target values at baseline. The number of glycemic excursions over 10 days decreased from 14.2 (5.4) at baseline to 10.2 (6.5) at 6 months with the duration decreasing by 214.0 minutes. Conclusion: In this large, real-world study of 12,000 Stelo users with suboptimally controlled T2D NIT, Stelo use was associated with meaningful improvements in glycemic control over 6 months with decreased glycemic excursions, suggesting potential benefits of Stelo to provide behavioral insights to support glucose management. Disclosure J. Layne: Employee; Current; Dexcom, Inc. A. Carite: Employee; Current; Dexcom, Inc. G. Aleppo: Advisory Panel; Current; Medscape, Tandem Diabetes Care, Inc. Consultant; Current; Eli Lilly and Company, Dexcom, Inc., Insulet Corporation. Research Support; Current; AbbVie Inc., Bayer, Fractyl, Insulet Corporation, MannKind Corporation, Tandem Diabetes Care, Inc., Medtronic. M. Peng: Employee; Current; Dexcom, Inc. V.N. Shah: Advisory Panel; Current; Abbott Diabetes, Dexcom, Inc. Advisory Panel; Ended; Medtronic. Advisory Panel; Current; Novo Nordisk, Eli Lilly and Company. Consultant; Current; Insulet Corporation, T1D Exchange. Advisory Panel; Current; Sanofi, Tandem Diabetes Care, Inc. Consultant; Ended; DreaMed Diabetes, Ltd. R.M. Bergenstal: Other - Advisory Panel, Consultant, Clinical Research Support; Current; Abbott Diabetes. Other - Consultant, Clinical Research Support; Current; Dexcom, Inc. Research Support; Current; Amgen Inc. Advisory Panel; Current; CeQur SA. Other - Advisory Panel, Consultant, Clinical Research Support; Current; Eli Lilly and Company. Research Support; Current; Insulet Corporation. Research Support; Ended; Luna. Research Support; Current; Medtronic. Other - Advisory Panel, Consultant, Clinical Research Support; Current; Novo Nordisk. Research Support; Current; Tandem Diabetes Care, Inc. Consultant; Current; Sanofi. Advisory Panel; Current; Vertex Pharmaceuticals Incorporated. Research Support; Current; Zealand Pharma A/S, Sequel, Embecta.